Novartis AG Common Stock (NVS)

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday.

This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.

AbbVie and other drugmakers may announce U.S. drug pricing deals on Friday as the White House pushes lower prices and Medicare payment reforms.

Salesforce Inc (NYSE:CRM) shares moved higher Wednesday after BTIG kicked off coverage with a Buy rating and a $335 price target, while the company scored a major win with Novartis choosing its Agentforce Life Sciences platform for global customer engagement.

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Novartis (NVS) offers a reliable 3.27% dividend yield, backed by strong profitability, a healthy balance sheet, and a history of consistent payouts.

Novartis reports Phase 3 results showing that combining ianalumab with eltrombopag significantly extends disease control and improves sustained platelet response in ITP patients.

As global trade tensions escalate dramatically throughout late 2024 and 2025, marked by a surge in protectionist policies and tit-for-tat tariffs, silver has emerged as a dual-threat asset: a critical safe-haven for investors fleeing economic uncertainty and a strategic industrial metal indispensable to the burgeoning green and high-tech economies. With

This low-cost international dividend ETF nearly doubled the S&P 500's return in 2025 -- but replicating that performance will require the stars to align once more.

This hot biotech stock could have a lot more room to run.

The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge, driven by an aging global population, the rising prevalence of chronic diseases, and relentless innovation in pharmaceutical research and development, signals

New York, NY – December 3, 2025 – In a significant move reverberating through the biotechnology sector, investment banking giant Morgan Stanley has downgraded Regeneron Pharmaceuticals (NASDAQ: REGN) from "Overweight" to "Equal-Weight." The firm maintained its price target of $767.00, signaling that, in their view, the stock is now fairly valued

Janux shares plunged after the JANX007 trial update prompted widespread target cuts, even as retail traders framed the selloff as poised for a rebound.

A weakening dollar makes this ETF more appealing.

These funds offer yields that are more than three times the S&P 500 average.

The company has a brand-new product to ship to pharmacies.

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function improvements.

FDA cleared Itvisma as the first gene-replacement therapy available to people 2 and older with the rare muscle-weakening condition.

Novartis (NVS) appears undervalued with a low P/E ratio, strong profitability, and solid financial health, making it a compelling stock for value investors.

European equity markets have experienced a significant resurgence around November 20, 2025, with major indices climbing as robust company results, particularly from the technology sector, have effectively soothed widespread concerns about an "AI bubble." This upturn signals renewed investor confidence in the region's economic stability and the tangible value being

Novartis raises long-term sales targets, boosts outlook for key medicines and outlines a pipeline strategy driving growth through 2030.